Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P060005/S026

IMMULITE Systems Free PSA

Siemens Medical Solutions Diagnostics Limited · Decision date Aug 20, 2026

FDA DECISIONP060005/S026

What did the FDA decide?

FDA records P060005/S026 as a supplement to PMA P060005, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 20, 2026.

FDA approval order statement

Approval of the change to the bead drying process used in the manufacture of bead components for the IMMULITE 2000 AFP, Free PSA, and PSA assays.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Immunology
Decision date
Aug 20, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P060005/S026
Regulatory pathway
PMA supplement
Product code
MTG
Decision code
OK30
Decision date
Aug 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions.

Product code
MTG
FDA device class
3

For the original device and its historical approval scope, see PMA P060005. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P060005 · Original PMA

    IMMULITE / IMMULITE 1000 AND IMMULITE 2000 FREE PSA ASSAYS

  2. P060005/S022 · Related supplement

    IMMULITE 2000 Systems Free Prostate-Specific Antigen (Free PSA)

  3. P060005/S026 received

    Application receipt date recorded by FDA.

  4. P060005/S026 · FDA decision

    30-Day Notice

  5. P060005/S027 · Related supplement

    IMMULITE Systems Free PSA

Timeline entries are records held by MedtechLedger for P060005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P060005

Explore the linked device profile

Other records with product code MTG

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Medical Solutions Diagnostics Limited

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Glyn Rhonwy Llanberis, Caernarfon, Gwynedd Ll55, 4EL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records